Quizartinib

Drug Profile

Quizartinib

Alternative Names: AC-010220; AC-220; ASP-2689

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • No development reported Acute lymphoblastic leukaemia; Solid tumours

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 01 Dec 2016 Phase-II clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Japan (PO) (NCT02984995) (JapicCTI163441)
  • 21 Nov 2016 Daiichi Sankyo plans a phase II trial for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Japan (PO) (JapicCTI163441)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top